Clinical trial · Interventional
The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma
The Clinical Value of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma
NCT03143140CI-TRIAL-00035340unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate a novel technique-ultrasound guided percutaneous abaltion of tumor feeding artery before RFA for liver malignancy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Neoplasms | Liver Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PAFA | Other | — | UNRESOLVED |
| tumor ablation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PAFA and tumor ablation
- description
- first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
- interventionNames
- Other: PAFA
- Other: tumor ablation
- type
- OTHER
- label
- tumor ablation
- description
- ablation of tumor directly
- interventionNames
- Other: tumor ablation
Primary outcomes (1)
- measure
- completed tumor necrosis
- timeFrame
- 1 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. tumor number ≤3， maximum tumor size ≤5cm; 2. accessibility of tumors via a percutaneous approach; 3. tumor feeding artery can be detected by 3D contrast enhance ultrasound; 4. platelet count ≥ 50,000/ml and INR \<1.6; 5. life expectancy more than 6 months 6. Child grade A or B Exclusion Criteria: 1. patients who scheduled liver transplantation 2. with extrahepatic metastasis 3. women during menstruation, pregnancy, child birth and baby nursing period 4. patients with severe mental disorder 5. cardiopulmonary failure
References
Publications (1)
- DERIVEDZhang ZY, Lee JC, Yang W, Yan K, Wu W, Wang YJ, Chen MH. Percutaneous ablation of the tumor feeding artery for hypervascular hepatocellular carcinoma before tumor ablation. Int J Hyperthermia. 2018;35(1):133-139. doi: 10.1080/02656736.2018.1484525. Epub 2018 Jul 12. PMID 29999436